Merck & Co., Inc. stock (US58933Y1055): Cancer portfolio drives growth amid patent and pricing questions

Merck & Co., Inc. has evolved into a central name in the global pharmaceuticals sector, with its stock drawing strong attention from US investors thanks to blockbuster cancer drug Keytruda, a broad vaccines business, and an active deal pipeline. While recent quarters have shown resilient revenue trends, the long-term narrative is shaped by patent expirations, US drug-pricing reforms, and how successfully Merck can translate its research and acquisitions into future cash flows.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

Merck & Co., Inc.: core business model

Merck & Co., Inc. operates as a global research-based pharmaceutical company focused on prescription medicines, vaccines, and animal health products. The group typically invests heavily in research and development to discover new therapies, guide them through multi-stage clinical trials, and secure regulatory approval from agencies such as the US Food and Drug Administration. Once a drug is approved, Merck commercializes it through its global sales and marketing infrastructure, targeting hospitals, clinics, physicians, and government programs while working with distributors and wholesalers.

A key feature of Merck’s model is the reliance on a relatively concentrated set of blockbuster products that generate a significant share of total revenue. These include oncology treatments, vaccines for both pediatric and adult populations, and specialty medicines in cardiovascular and immunology indications. Because patents eventually expire, Merck continually seeks to replenish its portfolio via internal discovery, in-licensing arrangements, and acquisitions of smaller biotech companies with promising pipelines.

The company also runs a sizable animal health business that provides vaccines and pharmaceutical products for livestock and companion animals. While smaller than the human health division, this segment broadens Merck’s exposure across end markets, benefiting from global demand for livestock productivity, food safety, and pet care. This diversification can help cushion revenue swings tied to individual human drugs while supporting the overall profitability profile.

Main revenue and product drivers for Merck & Co., Inc.

On the human health side, the most prominent revenue driver for Merck & Co., Inc. is the oncology franchise, and in particular the immuno-oncology therapy Keytruda. Keytruda has secured approvals across a wide range of cancer indications, including lung, melanoma, head and neck, kidney, and certain types of gastrointestinal tumors. Each new indication can expand the addressable patient population and extend the product’s lifecycle, making the oncology pipeline and trial outcomes critical to Merck’s growth prospects.

Another significant pillar of Merck’s revenue mix is vaccines. The company markets pediatric vaccines such as those targeting measles, mumps, rubella, and varicella, along with adult-focused products including shingles and human papillomavirus vaccines. These vaccines benefit from public immunization programs, employer-backed health plans, and global initiatives that support broad vaccination coverage, particularly in developed markets like the United States and Europe, but also in selected emerging regions.

Beyond oncology and vaccines, Merck maintains a portfolio of cardiovascular, diabetes, and hospital acute-care drugs that contribute meaningfully to revenue. These therapies address widespread conditions and often compete in crowded markets, which can put pressure on pricing and margins. However, even mature products can play an important role in cash generation, helping to fund research and development spending and dividend distributions. The animal health segment adds an additional revenue stream from livestock and companion animals, where long-term trends in protein consumption and pet ownership can support steady demand.

Conclusion

Merck & Co., Inc. occupies a prominent position in the global pharmaceutical landscape, anchored by its oncology and vaccines franchises and reinforced by a diversified portfolio that includes animal health. The business model is centered on high-intensity research, regulatory expertise, and global commercialization, which together can translate scientific advances into sustained cash flows. For US-focused investors, the company represents exposure to long-term trends in cancer care, immunization, and animal health, while also embodying sector-wide challenges around patent expirations, pricing debates, and regulatory scrutiny. Future performance is likely to hinge on the durability of its existing blockbusters, the success of its late-stage pipeline, and the ability of management to navigate policy developments and competitive dynamics without relying on any single product for growth.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.